CASI PHARMACEUTICALS INC (CASI) Stock Price, Forecast & Analysis
USA - NASDAQ:CASI - KYG1933S1012 - Common Stock
CASI Key Statistics, Chart & Performance
The current stock price of CASI is 1.38 USD. In the past month the price decreased by -30.3%. In the past year, price decreased by -74.82%.
CASI Latest News, Press Relases and Analysis
CASI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About CASI
Company Profile
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The firm is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The firm is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Company Info
CASI PHARMACEUTICALS INC
1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District
Beijing BEIJING 20850 CN
CEO: Wei-Wu He
Employees: 233
Phone: 861065618789
CASI PHARMACEUTICALS INC / CASI FAQ
Can you describe the business of CASI PHARMACEUTICALS INC?
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The firm is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The firm is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Can you provide the latest stock price for CASI PHARMACEUTICALS INC?
The current stock price of CASI is 1.38 USD. The price increased by 3.76% in the last trading session.
Does CASI stock pay dividends?
CASI does not pay a dividend.
What is the ChartMill rating of CASI PHARMACEUTICALS INC stock?
CASI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the expected growth for CASI stock?
The Revenue of CASI PHARMACEUTICALS INC (CASI) is expected to decline by -47.39% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for CASI PHARMACEUTICALS INC?
CASI PHARMACEUTICALS INC (CASI) currently has 233 employees.
Who owns CASI PHARMACEUTICALS INC?
You can find the ownership structure of CASI PHARMACEUTICALS INC (CASI) on the Ownership tab.
CASI Technical Analysis
CASI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CASI. CASI may be in some trouble as it scores bad on both profitability and health.
CASI Financial Highlights
Over the last trailing twelve months CASI reported a non-GAAP Earnings per Share(EPS) of -2.8. The EPS decreased by -37.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -150.05% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CASI Forecast & Estimates
7 analysts have analysed CASI and the average price target is 4.08 USD. This implies a price increase of 195.65% is expected in the next year compared to the current price of 1.38.
For the next year, analysts expect an EPS growth of 9.77% and a revenue growth -47.39% for CASI